ViroPharma's VP20621 meets C. difficile endpoint

ViroPharma Inc. (NASDAQ:VPHM) said once-daily VP20621 met the primary endpoint in a Phase II trial to prevent recurrent Clostridium difficile infections (CDI). Specifically, all doses of VP20621 incr...